Aktienanalyse zu Moderna Inc (MRNA)MRNAModerna Inc

Moderna, Inc. is a biotechnology company advancing a new class of medicines made of messenger ribonucleic acid (mRNA). It is engaged in developing medicines across infectious disease vaccines, oncology therapeutics and rare disease therapeutics. Its platform incorporates advances across three components, mRNA, delivery, and the manufacturing process, to advance its medicines. Its products are Spikevax and mNEXSPIKE (its COVID vaccines), and mRESVIA (its vaccine against respiratory syncytial virus (RSV)). It also has a diverse development pipeline that consists of 35 therapeutic and vaccine programs, six of which are in late-stage development. It has regulatory filings under review for its seasonal flu+COVID vaccine (mRNA-1083) in Europe and Canada and for its seasonal flu vaccine (mRNA-1010) in the United States, Europe, Canada and Australia. Its rare disease programs are Propionic acidemia (mRNA-3927); Methylmalonic acidemia (mRNA-3705), and Cystic Fibrosis (mRNA-3692/VX-522). It operates in the Healthcare sector (BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES) industry).

Moderna Inc is a good buy right now, as it has recently surged 14.21% to a current price of $225 following positive news about a new cancer research initiative. The stock has a strong momentum indicated by an RSI of 77.157, suggesting it is in a bullish trend. However, analysts have mixed views, with targets ranging from $80 to $200, indicating potential volatility. The main risk is the significant insider selling, which has increased by 437.15% over the last quarter, suggesting caution among insiders.